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Abstract
Background: Structural rearrangements of chromosomal band 19q13 are a non-random cytogenetic abnormality in
thyroid adenomas and adenomatous goiters and lead to an expression of miRNAs of the chromosome 19 microRNA
cluster C19MC. Normally, expression of these miRNAs is silenced except for embryonic stem cells and the placenta
where they represent the majority of miRNAs not only in the trophoblast but also in exosomes derived from it.
Presentation of the hypothesis: We have advanced the hypothesis that as part of the feto-maternal communication
miRNAs of C19MC serve immunomodulatory functions in the placenta and confer a growth advantage to thyroid
nodules by protecting them against autoimmune attacks. More precisely, the exosomes containing these miRNAs may
specifically target immune cells in their local environment as well as systemically by transferring their cargo to recipient
cells. Within these target cells the transferred miRNAs can interact with mRNAs of the recipient cells thereby
suppressing their immune-specific functions.
Testing the hypothesis: Experiments used to demonstrate the immunomodulatory capacity of placenta-derived
exosomes can be modified by transfecting the target cells with those miRNAs of C19MC represented in placental
exosomes.
Implications of the hypothesis: Mimics of C19MC-derived miRNAs might develop to useful drug candidates for the
treatment of autoimmune disease as e.g. rheumatoid arthritis and Sjögren’s syndrome and for the prevention of
transplant rejection. In case of tumor entities with elevated expression of C19MC miRNAs these miRNAs may be
interesting targets for treatment with appropriate antagonists.
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Background
First being described in 1989 [1], structural rearrange-
ments of chromosomal band 19q13 are a frequent non-
random cytogenetic abnormality in thyroid adenomas and
adenomatous goiters. By applying molecular-cytogenetic
methods on established cell lines it was possible to narrow
down the breakpoints to a region of about 150 kbp [2]
which was later shown to harbor C19MC (chromosome
19 microRNA cluster), the largest human microRNA clus-
ter at all [3] (Figure 1). As a rule, by the chromosomal
rearrangements the microRNAs of this cluster and the
neighboring miR-371-3 cluster become strongly upregu-
lated [4]. Of these both clusters C19MC is remarkable not
only because of its sheer size encoding more than 50 ma-
ture microRNAs but also because of its “young” age. The
whole cluster is primate-specific [3] and thus must have
evolved within a relatively short time in terms of evolution.
Normally, the miRNAs of C19MC are expressed almost
exclusively in embryonic stem cells [5-9] and, later during
embryonic and fetal development, only in the placenta
[3,10]. Luo et al. [11] demonstrated that the trophoblast
secretes exosomes, i.e. small membrane microvesicles,
which contain placenta-specific miRNAs. Moreover, it was
demonstrated quite recently that the vast majority of miR-
NAs packed into placenta-derived exosomes consist of
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cases, i.e. in the placenta or after chromosomal transloca-
tions in benign thyroid nodules, the exact mechanisms by
which C19MC miRNAs contribute to normal or aberrant
functions, respectively, remain obscure.
Herein, we shall advance the hypothesis that as part of
the feto-maternal communication miRNAs of C19MC
serve immunomodulatory functions in the placenta and,
once re-expressed due to chromosomal translocations,
confer a growth advantage to thyroid nodules by protect-
ing them against autoimmune attacks.
Presentation of the hypothesis
Though cytogenetic aberrations of 19q13.4 as detected in
benign thyroid lesions represent one of the most common
specific chromosomal alterations in epithelial tumors at all
the molecular mechanisms resulting from these frequent
genomic alterations still remain obscure. As to tumorigen-
esis, the stimulation of invasive growth has been attributed
to some miRNAs of C19MC [for review see 13] but
the activation of the cluster in thyroid adenomas and
nodular goiters with 19q13.4 alterations apparently does
not coincide with invasive growth. Thus, it seems un-
likely that in general activation of C19MC leads to inva-
sive growth or other features characterizing malignant
cells. On the other hand, presumed “physiological func-
tions” of its miRNAs might give us a clue to understand
their role in tumorigenesis. Of note, until birth expres-
sion of C19MC persists only in the placenta or, more
precisely, its trophoblast [10,11], and is expressed exclu-
sively from the paternal allele whereas the maternal al-
lele is silenced by epigenetic modification [14].
In general, miRNAs do not necessarily exert their main
functions in the cells they are expressed in since consider-
able amounts of miRNAs can become packed into micro-
vesicles called exosomes. Exosomes are bioactive vesicles
derived from endosomal membranes and involved in
intercellular communication by their specific cargos of
proteins, mRNAs, and miRNAs [for review see 15]. In
previous reports placenta-derived exosomes have been
demonstrated to interact with immune cells, e.g. resulting
in suppression of T-cell signaling components [16,17].
Figure 1 (A) Partial karyotype of an adenoma with an apparently balanced translocation t(1;19)(q32;q13.4) is shown as an example of
adenomas with a 19q13.4 chromosomal rearrangement. (B) Metaphase of a thyroid adenoma with a t(1;19)(q32;q13.4) after FISH with dual-color
break-apart rearrangement probe appropriate for the detection of 19q13.4 rearrangements. The 19q13.4 rearrangement is indicated by one single
green and one single red signal each. (C) The chromosomal region 19q13.4 with the miRNA clusters C19MC and miR-371-3 (pink boxes) and
surrounding protein-coding genes (blue boxes). The common breakpoint cluster of thyroid adenomas and adenomatous goiters is indicated by an
arrow.
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that the cellular miRNA composition of human primary
trophoblast cells strongly resembled that of the exosomes
secreted from these cells. In both cases those of C19MC
represented the majority of mature miRNAs. Of note, six
microRNAs of C19MC ranged among the top-ten exoso-
mal miRNAs. Based on their findings the authors have
assumed that these miRNAs “may play an important role
in placental-maternal communication, possibly directing
maternal adaptation to pregnancy.”
Herein, we would like to outline the hypothesis that
as one major function miRNAs of C19MC prevent the
embryo from being attacked by the maternal immune
system. Immunologically, the embryo is considered being
a semi-allograft and in case of egg donation even a full
allograft [18]. Nevertheless, the embryo efficiently avoids
rejection by its mother’s immune system by mechanisms
that are not fully understood yet [for review see 19]. Exo-
somes are known to share membrane characteristics with
the cells they are derived from [20]. Thus, it seems tempt-
ing to assume that they act like decoy-flairs for a jet. The
exosomes can specifically target immune cells in their
local environment, i.e. the decidua, as well as systemically
thereby transferring their cargo when melting with the
membrane of recipient cells. Within these target cells the
transferred miRNAs can interact with mRNAs of the
recipient cells thereby modulating post-transcriptional
regulation. Non-specific systemic side effects of this mech-
anism may be the mild immunosuppression noted during
pregnancy e.g. leading to the improvement of rheumatoid
arthritis [for review see 21].
Tracing back to nodular goiters and thyroid adenomas
re-expression of C19MC may protect cells against auto-
immune attacks. Of note, a considerable percentage of
these lesions develop after a pre-existing autoimmune dis-
ease of the thyroid.
Finally, the question arises if malignant tumors can
adopt this mechanism to protect themselves. 19q13 is one
of the most frequent chromosomal breakpoints identified
in human tumors and even if, in particular in case of com-
plex karyotypic aberrations, the small size of chromosome
19 may have resulted in false positive identification of this
breakpoint there remain a number of tumor entities where
its involvement has been identified unambiguously as e.g.
hamartoma of the liver [22,23]. Also, a number of recent
papers point to the role of amplification (e. g. in CNS-
PNET [24] and in embryonal brain tumors with ependy-
moblastic multilayered rosettes [25]) or undermethylation
of the C19MC locus (e. g. in hepatocellular carcinomas
[26,27]) in several tumor entities.
Testing the hypothesis
There are straightforward appropriate experimental
approaches to test our hypothesis. Nevertheless, these
approaches are time consuming because not all miRNAs
of the cluster may have the capacity to modulate immune
cells and because different types of immune cells have to
be tested. As a first step the same experiments used to
demonstrate the immunomodulatory capacity of placenta-
derived exosomes [e.g. 17] can be modified by transfecting
the target cells with those miRNAs of C19MC highly
represented in placental exosomes. Furthermore, it did
not escape our attention that mesenchymal cells from
the amniotic membrane have strong immunomodula-
tory properties, e.g. by actively suppressing T-cell prolif-
eration induced by alloantigens [28]. So far, it is believed
that at term only the trophoblast expresses C19MC
miRNAs but if our hypothesis holds true one would ex-
pect that these amniotic-membrane derived cells do so
as well.
Implications of the hypothesis
If the hypothesis holds true it will be not only relevant
in terms of basic science but also for several clinical
approaches. Mimics of C19MC-derived miRNAs, either
encapsulated or not, might develop to useful drug candi-
dates for the treatment of autoimmune disease as e.g.
rheumatoid arthritis and Sjögren’s syndrome. Likewise,
these miRNAs may prolong the maintenance of func-
tional allografts. On the other hand, in case of tumor en-
tities with forced expression of C19MC miRNAs their
antagonists may represent interesting alternatives for
targeted treatments.
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